Biopharma Shares Multiple 2025 Catalysts
Research Report
Tech Innovator Achieves Breakthrough Multi-Market Success
Advanced AI Solutions Deliver Hope for CNS Cancer Treatment
AI-Driven Discovery Unveils Cancer Therapy Breakthrough, Exceeding Projections
Pharma Innovator Reveals Groundbreaking Diabetes Treatment
Research Report
Biotech Advances Breakthrough Cancer Treatment Results
Research Report
Should You Double Down on This Story Stock?
Contributed Opinion
AI Company Unlocks Breakthrough Medical Diagnostics Platform
One company being listed on Cboe Canada starting January 8 is using AI and smartphones to help patients get quick and accurate diagnosis of their sore throats, helping to battle microbial resistance that threatens the effectiveness of antibiotics worldwide.Revenue Surge and Breakthrough Margins Fuel Growth in Critical Care Tech
CytoSorbents Corp. (CTSO:NASDAQ) reported a 22%-25% revenue jump in Q4, driven by strong performance and expanding global adoption of its flagship product. Read how regulatory breakthroughs in 2025 could redefine the company's market presence.Pharma Innovator Unlocks Multi-Disease Treatment Potential
Research Report
Quince Therapeutics Inc. is "positioned for a transformative year" in 2025 with a solid cash position of US$47.8 million as of the third quarter of 2024. Find out why one analyst gives the stock a Buy rating. Drug Innovator Launches Pivotal Cancer Trial Breakthrough
Research Report
Corvus Pharmaceuticals, Inc. (CRVS:NASDAQ) has the potential to generate hundreds of millions of dollars over the next decade with its drug candidates, an H.C. Wainwright & Co. analyst wrote in a January 2 research note. Miami Biopharma Sells Part of Business and Begins New Clinical Trial
Research Report
Miami biopharmaceutical company Veru Inc. (VERU:NASDAQ) recently sold its FC2 Female Condom business for US$18 million, and has begun enrolling patients for its The Phase 2b QUALITY trial of enobosarm in combination with Wegovy (semaglutide) for sarcopenic obesity. Read on to see why one analyst gives this company a Buy rating. Analyst Sees Major Growth for Biopharma With Weight-Loss Drug
Research Report
Recent successes of weight-loss drugs like Ozempic and Wegovy have led H.C. Wainwright & Co. Analyst Ed Arce to be "intrigued" by MetaVia Inc.'s (MTVA:NASDAQ) new drug candidate. Analyst Initiates Coverage of Co. With 'Once-in-a-Generation' Drug
Research Report
NewAmsterdam Pharma Company N.V.'s (NAMS:NASDAQ) drug obicetrapib is a "once-in-a-generation" drug for cardiovascular disease, an analyst wrote in a research note while initiating coverage on the company. See what rating the stock got and its price per share target. Parkinson's Treatment Advancements: Clinical Trials Begin for Potential New Therapy
Gain Therapeutics Inc. (GANX:NASDAQ) has announced the initiation of its Phase 1b clinical trial for GT-02287, a lead candidate targeting Parkinsons disease (PD), following regulatory approval in Australia. Read more about the trial aiming to redefine Parkinsons treatment and its potential global impact.Maryland Biotech Gains Regulatory Approval
Research Report
Gain Therapeutics Inc. (GANX:NASDAQ) recently received Australian regulatory approval to begin GT-02287 evaluation in Parkinson's disease (PD) patients. 
Streetwise Key Charts
